Court idles Sun-Ranbaxy deal

Share this article:

Insider-trading allegations have temporarily halted the Sun-Ranbaxy merger. The Wall Street Journal reports a court put a halt to the $3-billion merger until after an investigation. The move means Daiichi Sankyo, owner of Ranbaxy, may have to hold onto its 65% ownership stake a little longer.

The attempted sell-off follows a series of regulatory missteps that exacted harsh measures, including the FDA banning products from four of Ranbaxy's sites.

While Daiichi Sankyo would no longer own Ranbaxy, the purchase agreement would give the company a 9% stake in the new Sun-Ranbaxy company.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.